Walleye Capital LLC Makes New $8.69 Million Investment in BioAge Labs, Inc. $BIOA

Walleye Capital LLC acquired a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 354,395 shares of the company’s stock, valued at approximately $8,686,000.

A number of other large investors have also made changes to their positions in BIOA. Janus Henderson Group PLC lifted its stake in shares of BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the period. Octagon Capital Advisors LP increased its stake in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after acquiring an additional 150,000 shares during the period. Vanguard Group Inc. increased its stake in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after acquiring an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in BioAge Labs in the 4th quarter valued at approximately $13,892,000. Finally, Geode Capital Management LLC raised its holdings in BioAge Labs by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after acquiring an additional 28,646 shares in the last quarter.

BioAge Labs Trading Up 1.6%

Shares of BIOA opened at $10.60 on Friday. The stock has a market cap of $486.54 million, a PE ratio of -4.45 and a beta of 0.93. BioAge Labs, Inc. has a 1 year low of $4.38 and a 1 year high of $25.95. The stock has a 50 day simple moving average of $19.47 and a 200-day simple moving average of $18.86.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million for the quarter. On average, sell-side analysts forecast that BioAge Labs, Inc. will post -2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BIOA has been the subject of a number of research reports. Roth Capital reissued a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. BTIG Research reiterated a “buy” rating and set a $40.00 price target on shares of BioAge Labs in a research note on Monday, August 3rd. Finally, Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, BioAge Labs currently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.